FDA Approved Medical Products for:

B-cell lymphomas

The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products.

Generic Name Tositumomab and iodine I 131 tositumomab
Trade Name
(Manufacturer Name)
Bexxar®
(GlaxoSmithKline)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Rituximab
Trade Name
(Manufacturer Name)
Rituxan® (injection)
(Genentech, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of non-Hodgkin's B-cell lymphoma.
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Ibritumomab tiuxetan
Trade Name
(Manufacturer Name)
Zevalin
(Cell Therapeutics, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin?s lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name idelalisib
Trade Name
(Manufacturer Name)
Zydelig
(Gilead Sciences, Inc)
Indication
The FDA has approved this product to be used in this manner.
(1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and (2) Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies; and (3) Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.
More Information about this product Drug Information Portal